GlassScriptPhysician profile
David H Kovaleski
NPI 1902872674
$247.45
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $52.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $115.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.14 | 2019-2020 | |
| Philips North America LLC | $31.04 | 2019-2020 | |
| Mylan Specialty L.P. | $19.13 | 2020 | |
| Medtronic Vascular, INC. | $13.07 | 2019 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.92 | 2019 | |
| Chiesi USA, INC. | $10.90 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kovaleski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.